Home

Exelixis, Inc. - Common Stock (EXEL)

44.46
+7.51 (20.31%)
NASDAQ · Last Trade: May 14th, 1:58 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Why Exelixis Stock Is Skyrocketing Todayfool.com
Via The Motley Fool · May 14, 2025
Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidancebenzinga.com
Exelixis beats Q1 estimates with strong Cabometyx sales, raises 2025 guidance, and begins Phase 1 trial of its novel NK cell engager, XB628.
Via Benzinga · May 14, 2025
Biotech Leader Exelixis Pops After Obliterating First-Quarter Profit Expectationsinvestors.com
The top-notch biotech company easily beat first-quarter profit expectations.
Via Investor's Business Daily · May 13, 2025
Exploring Exelixis's Earnings Expectationsbenzinga.com
Via Benzinga · May 12, 2025
EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidatechartmill.com
EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidate
Via Chartmill · May 1, 2025
Is the Market Bullish or Bearish on Exelixis?benzinga.com
Via Benzinga · April 29, 2025
Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock.chartmill.com
A fundamental and technical analysis of (NASDAQ:EXEL): EXELIXIS INC (NASDAQ:EXEL) may be suited for high growth investing, we'll explore why in this article.
Via Chartmill · March 10, 2025
Peering Into Exelixis's Recent Short Interestbenzinga.com
Via Benzinga · March 3, 2025
Earnings Scheduled For May 13, 2025benzinga.com
Via Benzinga · May 13, 2025
For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering.chartmill.com
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Via Chartmill · April 28, 2025
Does EXELIXIS INC (NASDAQ:EXEL) align with Mark Minervini’s trading strategy?chartmill.com
A fundamental and technical analysis of (NASDAQ:EXEL): Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock.
Via Chartmill · April 25, 2025
Expert Outlook: Exelixis Through The Eyes Of 19 Analystsbenzinga.com
Via Benzinga · April 17, 2025
Why EXELIXIS INC (NASDAQ:EXEL) is Poised for High Growth.chartmill.com
Exploring high growth characteristics of EXELIXIS INC (NASDAQ:EXEL). A fundamental and technical analysis of (NASDAQ:EXEL).
Via Chartmill · April 16, 2025
EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock and is consolidating.chartmill.com
Based on a technical and fundamental analysis of NASDAQ:EXEL we can say: EXELIXIS INC (NASDAQ:EXEL), a strong growth stock, setting up for a breakout.
Via Chartmill · April 14, 2025
For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering.chartmill.com
EXELIXIS INC was identified as a growth stock that isn't overvalued. NASDAQ:EXEL is excelling in various growth indicators while maintaining a solid financial footing.
Via Chartmill · April 5, 2025
EXELIXIS INC (NASDAQ:EXEL) stands out as a stock that provides good value for the fundamentals it showcases.chartmill.com
EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price.
Via Chartmill · April 3, 2025
The Smartest Biotech Stocks to Buy With $50fool.com
Via The Motley Fool · April 3, 2025
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumorsbenzinga.com
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer.
Via Benzinga · March 26, 2025
Looking Into Exelixis's Recent Short Interestbenzinga.com
Via Benzinga · March 25, 2025
EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move.chartmill.com
Based on a technical and fundamental analysis of NASDAQ:EXEL we conclude: EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill · March 22, 2025
What 25 Analyst Ratings Have To Say About Exelixisbenzinga.com
Via Benzinga · March 13, 2025
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation.chartmill.com
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Via Chartmill · March 13, 2025
Is This The Beginning? Insights On Bearish Distribution Patternstalkmarkets.com
Discover the characteristics of a bearish distribution and the criteria the S&P 500 needs for a technical rally.
Via Talk Markets · March 12, 2025
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Mondaybenzinga.com
Via Benzinga · February 24, 2025
Why Exelixis Stock Trounced the Market on Thursdayfool.com
Via The Motley Fool · February 21, 2025